Skip to main content
European Commission logo print header

A treatment planning model for targeted radionuclide therapy

Obiettivo

Targeted radionuclide therapy (TRT) has been used as a systemic treatment modality for a range of cancers for 70 years. Its use will increase in Europe as new treatments are introduced into the clinic. However, quantitative analysis of energy deposition ha s seldom been carried out, and treatment strategies vary widely between centres. Internal dosimetry is becoming increasingly necessary to fully assess and compare treatment strategies.This project will develop methodologies to formulate treatment planning for TRT, as is carried out routinely for external beam radiotherapy, and as is required by a recent European directive. Two main aspects will be considered; internal dosimetry and fractionation administration. Techniques for cellular dosimetry will be expl ored and the absorbed doses at this scale will be calculated for radionuclides used for therapy. This information is necessary to help determine the optimal radionuclides to treat patients with metastatic spread and minimal residual disease.At present the number and level of radioactive fractions administered for any given therapy varies widely across Europe. The methodology to quantitatively analyse and compare fractionation options will be developed, and the relevant parameters will be examined in isolati on and in terms of their interactions. An accurate method to compare absorbed doses with successive treatments will be developed to enable treatment to be monitored and modified as it progresses.Results from the internal dosimetry and the fractionation stu dy will be used to form a theoretical and computational model for treatment planning. This model will be applied to clinical data acquired from I-131 mIBG therapy for adult and paediatric neuroendocrine disease and Y-90 monoclonal antibody therapy of lymph oma. This translational research project will provide support for clinical decision making and will provide the evidence base necessary to further optimise treatment on an individual patient basis.

Invito a presentare proposte

FP6-2002-MOBILITY-5
Vedi altri progetti per questo bando

Coordinatore

INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
Contributo UE
Nessun dato
Indirizzo
123 OLD BROMPTON ROAD
LONDON
Regno Unito

Mostra sulla mappa

Collegamenti
Costo totale
Nessun dato